The U.S. Supreme Court on May 4, 2026, temporarily restored nationwide access to the abortion pill mifepristone via telehealth, mail, and pharmacies, halting a lower-court order that had required in-person medical visits.
The one-week stay provides immediate relief for millions of patients while the justices consider the full case, which pits abortion-rights groups against states seeking tighter restrictions.
The ruling reverses a recent appeals-court decision backed by anti-abortion advocates and marks a significant victory for reproductive-rights organizations that warned the restrictions would create a de-facto ban in many states.
Abortion-rights groups hailed the move as a safeguard for medication abortion, which accounts for more than half of U.S. abortions. Opponents, however, condemned the Court for “judicial activism” and vowed to continue legal challenges.
Legal experts note the decision buys time but does not resolve the underlying dispute over FDA approvals for mifepristone, first authorized in 2000. The case has become a flashpoint in the post-Roe landscape, with conservative states pushing limits and Democrats framing access as a core right. Public reaction split sharply along partisan lines, with protests planned in major cities this week.
The temporary order comes as other reproductive-health battles rage in Congress and state legislatures. Analysts say the Court’s intervention underscores how abortion remains one of the most divisive issues in American politics nearly four years after Roe v. Wade was overturned.
For patients in rural or restrictive states, advocates say the restored mail option is literally lifesaving. The justices are expected to issue a more permanent ruling soon, potentially reshaping access for years to come.
